Similar Clinical Improvement Rates Among Biologic Drug Classes in Crohn's Disease: Systematic Review and Meta-Regression.

We conducted a systematic review and metaregression of pivotal Crohn’s disease trials to evaluate the rates of change in Crohn’s Disease Activity Index scores in patients receiving biologic treatments. The speed of clinical improvement was similar among biologic drug classes.

[1]  B. Sands,et al.  OP02 Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE study , 2021 .

[2]  J. Marshall,et al.  Comparative Efficacy and Rapidity of Action for Infliximab vs. Ustekinumab in Biologic Naive Crohn's Disease. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  R. Xu,et al.  Efficacy and Speed of Induction of Remission of Infliximab vs Golimumab for Patients With Ulcerative Colitis, Based on Data From Clinical Trials. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  B. Feagan,et al.  Rapid Response to Vedolizumab Therapy in Biologic‐Naive Patients With Inflammatory Bowel Diseases , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  G. D'Haens,et al.  Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn’s Disease: A Systematic Review , 2018, Clinical Gastroenterology and Hepatology.

[6]  S. Hanauer,et al.  A108 USTEKINUMAB IV INDUCTION RESULTS IN CROHN’S DISEASE SYMPTOM IMPROVEMENT WITHIN THE FIRST WEEK IN ANTI-TNF REFRACTORY PATIENTS , 2018 .

[7]  P. Gibson,et al.  Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told? , 2017, World journal of gastroenterology.

[8]  M. Vandervoort,et al.  A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity , 2015, Alimentary pharmacology & therapeutics.

[9]  Elaine L. Zanutto,et al.  Assessing Drug Treatment Preferences of Patients with Crohn’s Disease , 2010 .